CLL MRD Flow Panel
Also known as: CLL Minimal Residual Disease Panel
Use
This test is designed to detect measurable residual disease (MRD) in patients with chronic lymphocytic leukemia using flow cytometry. It provides sensitive detection of CLL-associated cell populations by immunophenotyping, which aids in assessing disease burden post-treatment and monitoring minimal residual disease.
Special Instructions
Not provided.
Limitations
Not provided.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
24 hours
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2-3 mL
Minimum Volume
Not provided
Container
EDTA preferred; sodium heparin acceptable
Storage Instructions
Refrigerate specimen; do not freeze; use cold pack during transport; pack not in direct contact with specimen
Causes for Rejection
Lithium heparin or ACD tubes not acceptable; failure to include recent CBC report
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | Within 72 hours of collection (48 hours for NY samples) |